Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FTT PET/CT in Glioblastoma
NCT04221061Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Feb 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]FluorThanatrace in glioblastoma (GBM) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Uptake of [18F]FTT in recurrent glioblastoma at 3 years. Started Feb 2020; status: terminated.
02
Drugs
[18F]FluorThanatrace
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04221061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221061.